Show simple item record

dc.contributor.authorLiang, Shi-bing
dc.contributor.authorLiang, Chang-Hao
dc.contributor.authorYang, Si-Hong
dc.contributor.authorLi, Yu-Qi
dc.contributor.authorTian, Zi-Yu
dc.contributor.authorRobinson, Nicola
dc.contributor.authorLiu, Jianping
dc.date.accessioned2020-02-28T09:11:51Z
dc.date.available2020-02-28T09:11:51Z
dc.date.issued2019-11-06
dc.description.abstract<i>Introduction</i> - Diarrhea-predominant irritable bowel syndrome (IBS-D) is a gastrointestinal disease with a high incidence and no effective drugs available. Compound Glutamine Entersoluble Capsules (CGEC) is a compound preparation integrating Sijunzi Decoction and L-Glutamine. The aim of this systematic review was to evaluate the clinical effects and safety of CGEC for IBS-D.<p> <p><i>Methods</i> - PubMed, Web of Science, the Cochrane library, CNKI, VIP and Wanfang Databases were searched from inception to June 30, 2019. Randomized controlled trials (RCTs) assessing the clinical effects and safety of CGEC for IBS-D were included. Global improvement of IBS-D symptoms was used as the primary outcome. The data were analyzed by RevMan5.3 software. Risk ratio (RR) calculations and 95% confidence intervals (CI) were used for dichotomous outcomes, and mean difference (MD) with 95% CI were used for continuous outcomes.<p> <p><i>Results</i> - Twelve RCTs involving 1232 participants were included. Compared with western conventional medicine (WCM) alone (i.e. gastrointestinal spasmodic and probiotics), CGEC demonstrated no significant differences in global improvement of IBS-D symptoms (RR 1.09, 95% CI [0.97, 1.23]), reduction in stool frequency (MD 0.14, 95% CI [−0.18, 0.46]) and relief of abdominal pain (MD 0.12, 95% CI [−0.27, 0.52]). The combination of CGEC and WCM had advantages over WCM alone in terms of global improvement of IBS-D symptoms (RR 1.37, 95% CI [1.25, 1.49]). Regarding the recurrence rate, both the CGEC group and the combined drug group were lower than the WCM group. In terms of safety, there is currently no evidence to suggest that CGEC can cause adverse reactions/events in patients with IBS-D.<p> <p><i>Conclusions</i> - Low or very low certainty evidence indicated that there was no difference between CGEC and WCM for the treatment of IBS-D. The combination of CGEC and WCM had a better therapeutic effect than WCM alone for the treatment of IBS-D.en_US
dc.identifier.citationLiang S, Liang, Yang, Li, Tian, Robinson N, Liu J. Clinical effects and safety of Compound Glutamine Entersoluble Capsules for diarrhea-predominant irritable bowel syndrome: A systematic review and meta-analysis. European Journal of Integrative Medicine. 2019;32:1-7en_US
dc.identifier.cristinIDFRIDAID 1763008
dc.identifier.doi10.1016/j.eujim.2019.101005
dc.identifier.issn1876-3820
dc.identifier.issn1876-3839
dc.identifier.urihttps://hdl.handle.net/10037/17549
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalEuropean Journal of Integrative Medicine
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2019 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleClinical effects and safety of Compound Glutamine Entersoluble Capsules for diarrhea-predominant irritable bowel syndrome: A systematic review and meta-analysisen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record